Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

HighWire full text link HighWire Free PMC article
Full text links

Actions

Share

Comparative Study
.2005 Dec 7;25(49):11231-8.
doi: 10.1523/JNEUROSCI.1724-05.2005.

Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors

Affiliations
Comparative Study

Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors

Daniela Popa et al. J Neurosci..

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) plays key roles in sleep-wakefulness regulation. Evidence indicates that 5-HT2 receptors are involved mainly in non-rapid eye movement sleep (NREMS) regulation and respiratory control. Here, we investigated the relative contribution of 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor subtypes to NREMS and breathing during sleep, using 5-HT2 subtype-selective ligands in wild-type (5-HT(2A)+/+) and knock-out (5-HT(2A)-/-) mice that do not express 5-HT(2A) receptors. Acute blockade of 5-HT(2A) receptors induced an increase in NREMS in 5-HT(2A)+/+ mice, but not 5-HT(2A)-/- mutants, which spontaneously expressed less NREMS than wild-type animals. In 5-HT(2A)+/+ mice, 5-HT(2B) receptor blockade produced a reduction of NREMS, whereas receptor activation induced an increase in this sleep stage. These effects were less pronounced in 5-HT(2A)-/- mice, indicating a lower sensitivity of 5-HT(2B) receptors in mutants, with no change in 5-HT(2B) mRNA. Blockade of 5-HT(2C) receptors had no effect on NREMS in both strains. In addition, an increase in EEG power density after sleep deprivation was observed in 5-HT(2A)+/+ mice but not in 5-HT(2A)-/- mice. Whole-body plethysmographic recordings indicated that 5-HT(2A) receptor blockade in 5-HT(2A)+/+ mice reduced NREMS apneas and bradypneas that occurred after sighs. In contrast, in 5-HT(2A)-/- mutants, NREMS apneas were not modified, and bradypnea after sighs were more pronounced. Our results demonstrate that 5-HT exerts a 5-HT(2B)-mediated facilitation of NREMS, and an influence respectively inhibitory on NREMS and facilitatory on sleep apnea generation, via 5-HT(2A) receptors. Moreover, 5-HT(2A) gene knock-out leads to functional compensations yielding adaptive changes opposite to those caused by pharmacological blockade of 5-HT(2A) receptors in 5-HT(2A)+/+ mice.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effects of acute treatment with the 5-HT2A receptor antagonist MDL 100907 at various doses (abscissa) on amounts of vigilance states in 5-HT2A+/+ (dotted line) and 5-HT2A–/– (solid line) mice. Data (mean ± SEM of 4–8 animals) are expressed as minutes during the first 3 postinjection hours. At the time of injection, there were no significant differences in amounts of vigilance states between 5-HT2A+/+ and 5-HT2A–/– mice. *p < 0.05, significantly different from vehicle (0 on abscissa);post hoc Bonferroni's–Dunn's test. Error bars represent SEM.
Figure 2.
Figure 2.
Amounts of W, NREMS, and REMS across the light/dark cycle in 5-HT2A+/+ (dotted line) and 5-HT2A–/– (solid line) mice. Data (mean ± SEM of 10 animals per group) are expressed as minutes per 3 h during 24 h. The black bar on the abscissa represents the dark period of the light/dark cycle.#p < 0.05, significantly different from 5-HT2A+/+ mice;post hoc Bonferroni's–Dunn's test. Error bars represent SEM.
Figure 3.
Figure 3.
Effects of 6 h of sleep deprivation starting at light onset on delta power, during four consecutive 2 h intervals of the recovery period in 5-HT2A+/+ (dotted line) and 5-HT2A–/– (solid line) mice. Statistical analysis was performed on EEG power values, and data (mean ± SEM of 9 animals in each group) are plotted as a percentage of the paired values obtained under control conditions. *p < 0.05, significantly different from respective control value;post hoc Bonferroni's–Dunn's test.#p < 0.05, significantly different from 5-HT2A+/+ value;post hoc Bonferroni's–Dunn's test. Error bars represent SEM.
Figure 4.
Figure 4.
Effects of acute treatment with the 5-HT2B/2C receptor antagonist SB 206553 (2.5 mg/kg, i.p.; hatched bars) on amounts of vigilance states in 5-HT2A+/+ (white bars) and 5-HT2A–/– (black bars) mice. Data (mean ± SEM of 7 animals per group) are expressed as minutes per hour during each of the first 3 postinjection hours. *p < 0.05, significantly different from paired-saline-treated animals;post hoc Bonferroni's–Dunn's test. Error bars represent SEM.
Figure 5.
Figure 5.
Effects of acute treatment with the 5-HT2C receptor antagonist SB 242084 at various doses (abscissa) on amounts of vigilance states in 5-HT2A+/+ (dotted line) and 5-HT2A–/– (solid line) mice. Data (mean ± SEM of 4–6 animals) are expressed as minutes during the first 3 postinjection hours. *p < 0.05, significantly different from vehicle (0 on abscissa);post hoc Bonferroni's–Dunn's test. Error bars represent SEM.
Figure 6.
Figure 6.
A, B, Effects of acute treatment with the 5-HT2B receptor antagonist SB 215505 (A) or the 5-HT2B receptor agonist BW 723C86 (B) at various doses on amounts of vigilance states in 5-HT2A+/+ (dotted line) and 5-HT2A–/– (solid line) mice. Data (mean ± SEM of 5–11 animals per group) are expressed as minutes during the first postinjection hour. *p < 0.05, significantly different from vehicle (0 on abscissa);#p < 0.05, significantly different from respective 5-HT2A+/+ value;post hoc Bonferroni's–Dunn's test. Error bars represent SEM.
Figure 7.
Figure 7.
5-HT2A, 5-HT2B, and 5-HT2C mRNA expression in the hypothalamus of 5-HT2A+/+ (white bars) and 5-HT2A–/– (black bars) mice. Results [relative quantity (RQ), mean ± SEM of 4 animals in each group] are expressed in arbitrary units (A.U.) after normalization to an endogenous reference gene (HPRT). Normalization with GADPH endogeneous gene (see Materials and Methods) yielded similar results.#p < 0.05, significantly different from respective 5-HT2A+/+ value; unpaired Student'st test. Error bars represent SEM.
Figure 8.
Figure 8.
Implication of 5-HT2A receptors in the dynamics of breathing after sighs. Sighs are followed by both an immediate and a delayed decrease in respiration frequency, and apnea occurs in these two phases of bradypnea.A, Example of plethysmograph recording of a sigh (0 on abscissa). a.u., Arbitrary units.B, Average rate of respiration after a sigh. Dotted lines correspond to ± SD.C, Distribution of apneas after a sigh; the counts of apneas have been normalized to the number of sighs (bin size, 0.5 s).A–C are from the same 5-HT2A+/+ mouse recorded from 10:00 A.M. to 4:00 P.M.D–F, The delayed decrease in breathing frequency after a sigh is almost completely suppressed after 5-HT2A receptor blockade by MDL 100907 in 5-HT2A+/+ mice but is more pronounced in 5-HT2A–/– mutants.D, Average changes in respiration frequency after a sigh in 5-HT2A+/+ during the first 3 h (between 10:00 A.M. and 1:00 P.M.) and during the next 3 h (between 1:00 P.M. and 4:00 P.M.) after MDL 100907 (2 mg/kg, i.p.) administration (n = 7). The rate of breathing is normalized to the rate before the sigh,E, Average changes in spontaneous respiration frequency after a sigh in 5-HT2A+/+ (n=14) and 5-HT2A–/– (n=12) mice. Recordings were made between 10:00 A.M. and 4:00 P.M.#,*p < 0.05, significantly different from vehicle or 5-HT2A+/+ mice, respectively; Student'st test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adrien J, Dugovic C, Martin P (1991) Sleep-wakefulness patterns in the helpless rat. Physiol Behav 49: 257–262. - PubMed
    1. Adrien J, Alexandre C, Boutrel B, Popa D (2004) Contribution of the “knock-out” technology to understanding the role of serotonin in sleep regulations. Arch Ital Biol 142: 369–377. - PubMed
    1. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306: 879–881. - PubMed
    1. Benca R (2000) Mood disorders. In: Principles and practice of sleep medicine (Kryger M, Roth T, Dement W, eds), pp 1140–1158. Philadelphia: Saunders.
    1. Benington JH, Heller HC (1995) Monoaminergic and cholinergic modulation of REM-sleep timing in rats. Brain Res 681: 141–146. - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
HighWire full text link HighWire Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp